Publications
Detailed Information
Prediction of treatment outcome in chronic hepatitis C patients based on early viral dynamics during high-dose induction interferon and ribavirin therapy
Cited 8 time in
Web of Science
Cited 7 time in Scopus
- Authors
- Issue Date
- 2005-05-28
- Publisher
- S. Karger AG
- Citation
- Intervirology 2005;48(4):230-238.
- Keywords
- Adult ; Antiviral Agents/administration & dosage/*therapeutic use ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Hepacivirus/*drug effects/physiology ; Hepatitis C, Chronic/*drug therapy/virology ; Humans ; Interferon Alfa-2a/administration & dosage/*therapeutic use ; Male ; Middle Aged ; Predictive Value of Tests ; RNA, Viral/blood ; Ribavirin/administration & dosage/*therapeutic use ; Treatment Outcome ; Viral Load
- Abstract
- OBJECTIVE: In chronic hepatitis C, early viral load decline after interferon administration is dose dependent and reflects the intrinsic viral susceptibility to the antiviral action of interferon. We examined whether the augmented suppression of susceptible viral loads by high-dose induction interferon could possibly discriminate responsive patients from non-responsive patients at an early stage of treatment. METHODS: Fifty-nine chronic hepatitis C patients were randomly allocated to receive one of two treatment regimens; 3 MU interferon three times weekly plus ribavirin 1,000 mg/day for 24 weeks in the CR group (n = 30), and the same regimen as in the CR group except 10 MU interferon daily for the first week in the HR group (n = 29). Changes in viral loads during the first week of treatment were analyzed in terms of sustained virological response (SVR). RESULTS: The positive predictive values of undetectable (<100 IU/ml) or low serum HCV RNA (<2,000 IU/ml) after 1 week of treatment for SVR were 100% in both treatment groups, whereas the negative predictive values of the low viral titer were 91% in the HR group and 70% in the CR group. CONCLUSION: One-week virological response to high-dose induction interferon/ribavirin combination therapy is more predictive of SVR than conventional combination therapy in chronic hepatitis C.
- ISSN
- 0300-5526 (Print)
- Language
- English
- URI
- http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15920347
https://hdl.handle.net/10371/10014
- Files in This Item:
- There are no files associated with this item.
- Appears in Collections:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.